SG11202011304QA - Compositions comprising pcsk9-binding molecules and methods of use - Google Patents

Compositions comprising pcsk9-binding molecules and methods of use

Info

Publication number
SG11202011304QA
SG11202011304QA SG11202011304QA SG11202011304QA SG11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA
Authority
SG
Singapore
Prior art keywords
pcsk9
compositions
methods
binding molecules
molecules
Prior art date
Application number
SG11202011304QA
Inventor
Tracy Mitchell
Richard Mealey
Original Assignee
Lib Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lib Therapeutics Llc filed Critical Lib Therapeutics Llc
Publication of SG11202011304QA publication Critical patent/SG11202011304QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
SG11202011304QA 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use SG11202011304QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672187P 2018-05-16 2018-05-16
PCT/US2019/032710 WO2019222529A1 (en) 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use

Publications (1)

Publication Number Publication Date
SG11202011304QA true SG11202011304QA (en) 2020-12-30

Family

ID=68540981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011304QA SG11202011304QA (en) 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use

Country Status (13)

Country Link
US (3) US10738102B2 (en)
EP (1) EP3793612A4 (en)
JP (1) JP2021523214A (en)
KR (1) KR20210010890A (en)
CN (1) CN112423790A (en)
AU (1) AU2019269617A1 (en)
BR (1) BR112020023344A2 (en)
CA (1) CA3115341A1 (en)
EA (1) EA202092778A1 (en)
MX (1) MX2020012214A (en)
SG (1) SG11202011304QA (en)
WO (1) WO2019222529A1 (en)
ZA (1) ZA202007107B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3793612A4 (en) * 2018-05-16 2022-03-02 LIB Therapeutics, LLC Compositions comprising pcsk9-binding molecules and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420098B2 (en) * 2010-04-13 2013-04-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to PCSK9
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
CN105246503A (en) * 2013-03-14 2016-01-13 第一三共株式会社 Novel binding proteins for pcsk9
EP3647322B1 (en) * 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
CA2943241C (en) * 2014-03-20 2023-09-19 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
CN107428817B (en) 2015-03-12 2022-07-12 免疫医疗有限责任公司 Method for purifying albumin fusion proteins
EP3793612A4 (en) * 2018-05-16 2022-03-02 LIB Therapeutics, LLC Compositions comprising pcsk9-binding molecules and methods of use

Also Published As

Publication number Publication date
CN112423790A (en) 2021-02-26
AU2019269617A1 (en) 2020-12-03
JP2021523214A (en) 2021-09-02
EA202092778A1 (en) 2021-05-27
US11692021B2 (en) 2023-07-04
AU2019269617A8 (en) 2020-12-17
KR20210010890A (en) 2021-01-28
CA3115341A1 (en) 2019-11-21
EP3793612A1 (en) 2021-03-24
US20230295270A1 (en) 2023-09-21
US10738102B2 (en) 2020-08-11
WO2019222529A1 (en) 2019-11-21
US20210002350A1 (en) 2021-01-07
EP3793612A4 (en) 2022-03-02
BR112020023344A2 (en) 2021-02-09
ZA202007107B (en) 2022-03-30
MX2020012214A (en) 2021-03-31
US20200071386A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
IL277889A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
GB2582100B (en) CAS12C Compositions and methods of use
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
EP3595653A4 (en) Compositions of plinabulin and use thereof
EP3435956A4 (en) Photo-stabilized compositions and methods of use
ZA201903165B (en) Coating compositions and methods of use thereof
ZA201906169B (en) Synthekine compositions and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL265761A (en) Terlipressin compositions and their methods of use
GB202105087D0 (en) Microbial compositions and methods of use
EP3953474A4 (en) Cancer-specific molecules and methods of use thereof
EP3574047A4 (en) Emulsion compositions and methods of their use
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
IL283782A (en) Anellosomes and methods of use
EP3600554A4 (en) Anti-pathogen composition and methods of use thereof
ZA202000502B (en) Cosmetic compositions and methods of use
GB2568562B (en) Moldable compositions and methods of using thereof
IL282533A (en) Oligosaccharide compositions and methods of use thereof
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
IL274563A (en) Methods of using and compositions containing dulaglutide
IL261794A (en) Compositions and methods of their use